Statin Therapy in Children

Sunil, Bhuvana; Ashraf, Ambika P.

doi:10.5772/intechopen.91367

Cited by 2 publications

(3 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the pediatric population, pravastatin, simvastatin, fluvastatin, atorvastatin and rosuvastatin have been studied, at a maximum dose of 40mg for pravastatin and simvastatin, 20mg for rosuvastatin and atorvastatin and at 80mg for fluvastatin. Pitavastatin has also been studied in children with FH and has gained approval by the FDA for children ≥8 years of age with HeFH [24][25][26] . Rosuvastatin lowers the development of increased intima-media thickness (IMT) over a 2-year period and a similar effect in adults can be achieved with atorvastatin within the same time frame.…”

Section: Statinsmentioning

confidence: 99%

A narrative review of treatment modalities for familial hypercholesterolemia

Samprokatsidis,

Antza,

Frangou

et al. 2023

JAPT

View full text Add to dashboard Cite

Familial Hypercholesterolemia (FH), a commonly missed disorder in a patient with abnormalities in lipid metabolism is described as a heritable disorder presenting elevated LDL cholesterol and lipid deposition in various tissues. This contributes to the early development of manifestations of atherosclerotic disease with the preterm occurrence of severe cardiovascular events. Apparently, decision-making is a strenuous effort and many individuals are underdiagnosed. FH affects LDL receptor and its function plays a critical role in the mechanism of many therapeutic modalities, thus alternative pathways must also be considered. This review addresses the main options of care in individuals with familial hypercholesterolemia along with unconventional drugs like mipomersen, inclisiran, lomitapide, gamcabene, and ANGLT3 inhibitors which have yielded important results for disease management.

show abstract

Section: Statinsmentioning

confidence: 99%

A narrative review of treatment modalities for familial hypercholesterolemia

Samprokatsidis,

Antza,

Frangou

et al. 2023

JAPT

View full text Add to dashboard Cite

show abstract

“…They have a favorable safety profile and excellent short-and long-term data with benefits outweighing the risks. The FDA has approved lovastatin (1987), pravastatin (1991), simvastatin (1991), fluvastatin (1993), atorvastatin (1996), rosuvastatin (2003), and pitavastatin (2009) 15 for use in children. The use of these medications is supported by multiple clinical trials, 13,[16][17][18][19][20][21][22][23][24][25] with significant LDL-C reduction, favorable effect on Recently, long-term follow-up data have showed that initiation of statin therapy during childhood in patients with FH slowed the atherosclerotic progression and reduced the risk of cardiovascular disease in adulthood.…”

Section: Therapeutic Agents That Reduce Hepatic Synthesis Of Cholesterolmentioning

confidence: 99%

“…They have a favorable safety profile and excellent short- and long-term data with benefits outweighing the risks. The FDA has approved lovastatin (1987), pravastatin (1991), simvastatin (1991), fluvastatin (1993), atorvastatin (1996), rosuvastatin (2003), and pitavastatin (2009) 15 for use in children. The use of these medications is supported by multiple clinical trials, 13,16–25 with significant LDL-C reduction, favorable effect on ASCVD risk and overall low adverse effects.…”

Section: Therapeutic Agents That Predominantly Lower Ldl-cmentioning

confidence: 99%

Novel therapeutic targets and agents for pediatric dyslipidemia

Sunil

Foster

Wilson

et al. 2021

Therapeutic Advances in Endocrinology

Self Cite

View full text Add to dashboard Cite

Landmark studies have convincingly demonstrated that atherosclerosis begins in youth. While generally asymptomatic, an increasing number of youth with disorders of lipid and lipoprotein metabolism, such as familial hypercholesterolemia, are being identified through selective and universal screening. While a heart healthy lifestyle is the foundation of treatment for all youth with dyslipidemia, lipid-lowering therapy may be required by some to prevent morbidity and premature mortality, especially when initiated at a young age. When appropriate, use of statins has become standard of care for reducing low-density lipoprotein cholesterol, while fibrates may be beneficial in helping to lower triglycerides. Many therapeutic options commonly used in adults are not yet approved for use in youth less than 18 years of age. Although currently available lipid-lowering therapy is well tolerated and safe when administered to youth, response to treatment may vary and some conditions lack an efficient therapeutic option. Thus, newer agents are needed to aid in management. Many are in development and clinical trials in youth are currently in progress but will require FDA approval before becoming commercially available. Many utilize novel approaches to favorably alter lipid and lipoprotein metabolism. In the absence of long-term outcome data of youth who were treated beginning at an early age, clinical registries may prove to be useful in monitoring safety and efficacy and help to inform clinical decision-making. In this manuscript, we review currently available and novel therapeutic agents in development for the treatment of elevated cholesterol and triglycerides.

show abstract

Statin Therapy in Children

Cited by 2 publications

References 83 publications

A narrative review of treatment modalities for familial hypercholesterolemia

A narrative review of treatment modalities for familial hypercholesterolemia

Novel therapeutic targets and agents for pediatric dyslipidemia

Contact Info

Product

Resources

About